Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Latest Research

Filter Results By

Filter Applied. Clear All

Latest Posts

December 20, 2024 Strengthening the Pro-Life Safety Net: Federal Transportation Policy Strengthening the Pro-Life Safety Net: Federal Transportation Policy December 19, 2024 End of Year Update: Tax Credits for Life Affirming Organizations End of Year Update: Tax Credits for Life Affirming Organizations December 19, 2024 Fact Sheet: Abortions at or after 15 Weeks in the United States Fact Sheet: Abortions at or after 15 Weeks in the United States
Reset All Filters
Maternal & Public Health

Primer: The Basic Biochemistry of Abortion Pill Reversal

This primer lays out the science behind Abortion Pill Reversal by examining the function of progesterone as a naturally occurring hormone in the female reproductive system, the functions of mifepristone and misoprostol as drugs used in drug-induced abortion, the basic biochemical principle of competitive inhibition, and the disinformation surrounding the role of progesterone in reversing the abortion drug.

OB-GYN: EMTALA Decision Will Force Doctors to End Patients’ Lives Through Elective Abortions
General

OB-GYN: EMTALA Decision Will Force Doctors to End Patients’ Lives Through Elective Abortions

In response to the U.S Supreme Court’s opinion in Idaho v. United States (also called Moyle v. United States), Ingrid Skop, M.D., FACOG, a board-certified OB-GYN who serves as vice president and director of medical affairs at Charlotte Lozier Institute, reacted.

Life & the Law

The State of Abortion Reporting in 2024 America: Still Striving Toward a Better National Standard

This paper evaluates each state’s abortion reporting requirements and publicly accessible abortion reports (or lack thereof). It is an update to CLI’s 2016 survey of abortion reporting across the country, and analyzes state-wide, regional, and national trends that could inform public health officials and policymakers.

Life & the Law

Written Testimony of Dr. Ingrid Skop on Interstate Travel for Abortion

On June 12, CLI VP of Medical Affairs Dr. Ingrid Skop testified on the issue of interstate travel for abortion before the Subcommittee on Federal Courts, Oversight, Agency Action, and Federal Rights of the U.S. Senate Committee on the Judiciary. Dr. Skop responded to a number of misconceptions about the alleged need for women to travel out of state for abortion.

Maternal & Public Health

Abortion Reporting: Arkansas (2023)

Arkansas reported zero abortions in 2023 as of June 3, 2024. 

Maternal & Public Health

Abortion Reporting: West Virginia (2023)

West Virginia’s 2023 abortion statistics by quarter were published throughout 2023 and into March 2024, showing that abortions in the Mountain State have decreased exponentially since 2022.

Maternal & Public Health

Abortion Reporting: Indiana (2023)

Indiana changed to quarterly reporting for 2023 and, as a result, this data represents the summation of the data in the quarterly reports. These reports showed that abortions in Indiana decreased significantly from 2022, likely due to the state’s life at conception law going back into effect in late August 2023.

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions
Life & the Law

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions

CLI's VP of Medical Affairs Ingrid Skop, together with Calum Miller, MD, and Kevin Duffy, MPH, recently published an article in Issues in Law & Medicine arguing that decisions by the FDA to pull back regulations on the abortion drug mifepristone in part relied on "flawed studies with significantly undercounted complications" from the U.K.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image